{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:03:00Z","timestamp":1787853780416,"version":"build-2784847793"},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatologic Therapy"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1111\/dth.12696","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T06:39:01Z","timestamp":1536734341000},"page":"e12696","source":"Crossref","is-referenced-by-count":24,"title":["Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus"],"prefix":"10.1155","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-8830","authenticated-orcid":false,"given":"Soheil","family":"Tavakolpour","sequence":"first","affiliation":[{"name":"Genomic Research Center; Shahid Beheshti University of Medical Sciences; Tehran Iran"},{"name":"Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences; Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"10.1111\/dth.12696-BIB0001|dth12696-cit-0001","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaut.2013.06.007","article-title":"Interleukin-7: Fuel for the autoimmune attack","volume":"45","author":"Dooms","year":"2013","journal-title":"Journal of Autoimmunity"},{"issue":"3","key":"10.1111\/dth.12696-BIB0002|dth12696-cit-0002","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jaci.2017.04.015","article-title":"Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials","volume":"140","author":"Han","year":"2017","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"10083","key":"10.1111\/dth.12696-BIB0003|dth12696-cit-0003","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1111\/dth.12696-BIB0004|dth12696-cit-0004","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.molimm.2006.11.025","article-title":"Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease","volume":"44","author":"O'Sullivan","year":"2007","journal-title":"Molecular Immunology"},{"issue":"6","key":"10.1111\/dth.12696-BIB0005|dth12696-cit-0005","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cytogfr.2013.09.001","article-title":"Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases","volume":"24","author":"Pan","year":"2013","journal-title":"Cytokine & Growth Factor Reviews"},{"key":"10.1111\/dth.12696-BIB0006|dth12696-cit-0006","first-page":"1","article-title":"Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: A review of literature","volume":"28","author":"Samadi","year":"2016","journal-title":"The Journal of Dermatological Treatment"},{"issue":"4","key":"10.1111\/dth.12696-BIB0007|dth12696-cit-0007","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.174379","article-title":"Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study","volume":"82","author":"Sharma","year":"2016","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"5","key":"10.1111\/dth.12696-BIB0008|dth12696-cit-0008","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/dth.12327","article-title":"Dupilumab: A revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus","volume":"29","author":"Tavakolpour","year":"2016a","journal-title":"Dermatologic Therapy"},{"key":"10.1111\/dth.12696-BIB0009|dth12696-cit-0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.intimp.2016.02.020","article-title":"Interleukin 21 as a new possible player in pemphigus: Is it a suitable target?","volume":"34","author":"Tavakolpour","year":"2016b","journal-title":"International Immunopharmacology"},{"key":"10.1111\/dth.12696-BIB0010|dth12696-cit-0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review","volume":"54","author":"Tavakolpour","year":"2018","journal-title":"International Immunopharmacology"},{"key":"10.1111\/dth.12696-BIB0011|dth12696-cit-0011","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cyto.2015.09.017","article-title":"Interleukin 4 inhibition as a potential therapeutic in pemphigus","volume":"77","author":"Tavakolpour","year":"2016","journal-title":"Cytokine"},{"issue":"10039","key":"10.1111\/dth.12696-BIB0012|dth12696-cit-0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdth.12696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/dth.12696\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:57:51Z","timestamp":1671818271000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.12696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"URL":"https:\/\/doi.org\/10.1111\/dth.12696","archive":["Portico"],"relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}